Simone S.
- Country
- Italy
- Department
- U.O.C. di Gastroenterologia ed Endoscopia Digestiva
Research Overview
- Evaluation of Mirikizumab Concentrations in Breast Milk Among Lactating Participants Receiving Subcutaneous Mirikizumab for Ulcerative Colitis or Crohn's Disease
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis
- Randomized, Double‑Blind, Placebo‑Controlled Trial of LY4268989 (Adipic Acid) in Adults with Moderately to Severely Active Ulcerative Colitis
Data & Insights
Has run more than one trial at 202 of 418 partner sites.
Specializations
Inflammatory Bowel Disease Management
This investigator specializes in treating complex inflammatory bowel conditions, with particular expertise in both Crohn's disease and ulcerative colitis.
- Standard and Refractory Crohn's Disease
- Fistulizing Perianal Complications
- Moderate to Severe Ulcerative Colitis
The research encompasses various manifestations of IBD, including challenging presentations requiring specialized therapeutic approaches.
Novel Therapeutic Applications
The investigator focuses on evaluating innovative biological therapies including mirikizumab, risankizumab, guselkumab, and etrasimod for inflammatory bowel conditions.
- Long-term Treatment Efficacy
- Alternative Treatment Pathways
- Therapeutic Drug Monitoring
Expertise extends to comparing treatment efficacy and implementing personalized therapeutic approaches.
Clinical Outcomes Assessment
The investigator specializes in evaluating long-term safety profiles and therapeutic efficacy in chronic inflammatory conditions.
- Extended Treatment Response
- Safety Monitoring
- Disease Activity Assessment
Focus includes comprehensive evaluation of treatment outcomes in inflammatory bowel conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.